eXoZymes Inc美股招股说明书(2025-04-01版)

4,013,769 SHARES OF COMMON STOCK This prospectus supplement updates and amends the prospectus dated November 11, 2024 (as supplemented to date, the“Prospectus”), which forms a part of our Registration Statement on Form S-1 (Registration Statement No. 333-276987) which wasdeclared effective by the SEC on November 8, 2024. The Prospectus and this prospectus supplement relate to the resale by the selling securityholder named in the Prospectus (the“selling securityholder”) of 4,013,769 shares of common stock, par value $0.000001 per share (the “Common Stock”). The Prospectusalso covers any additional securities that may become issuable by reason of stock splits, stock dividends or other similar transactions. This prospectus supplement should be read in conjunction with the Prospectus, which is to be delivered with this prospectussupplement. This prospectus supplement updates, amends and supplements the information included or incorporated by reference inthe Prospectus. If there is any inconsistency between the information in the Prospectus and this prospectus supplement, you shouldrely on the information in this prospectus supplement. This prospectus supplement is not complete without, and may not be delivered or utilized except in connection with, theProspectus, including any amendments or supplements to it. Annual Report on Form 10-K On March 31, 2025, the we filed the Annual Report on Form 10-K for the year ended December 31, 2024, with the SEC. TheAnnual Report on Form 8-K is attached hereto. We are an “emerging growth company,” as defined under the federal securities laws, and, as such, may elect to complywith certain reduced public company reporting requirements for future filings. Investing in our securities involves a high degree of risk. Before buying any securities, you should carefully read thediscussion of the risks of investing in our securities in the section titled “Risk Factors” beginning on page 8 of the Prospectusand beginning on page 14 of the Annual Report. You should rely only on the information contained in the Prospectus, this prospectus supplement, or any furtherprospectus supplement or amendment hereto. We have not authorized anyone to provide you with different information. Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved ofthese securities or determined if this prospectus is truthful or complete. Any representation to the contrary is a criminaloffense. The date of this prospectus supplement is April 1, 2025. UNITED STATESSECURITIES AND EXCHANGE COMMISSIONWashington, D.C. 20549 FORM 10-K ☒ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE ANNUAL PERIOD ENDED DECEMBER 31, 2024 OR ☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number:001-42204 EXOZYMES INC.(Exact name of registrant as specified in its charter) (626) 415-1488(Registrant’s telephone number, including area code) Securities registered pursuant to Section 12(b) of the Exchange Act: None Name of each exchange on which registered Nasdaq Capital Markets EXOZ Securities registered pursuant to Section 12(g) of the Act: None Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.Yes☐No☒. Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.Yes☒No☐. Indicate by check mark whether the issuer (1) has filed all reports required to be filed by Section 13 or 15(d) of the Exchange Actduring the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has beensubject to such filing requirements for the last 90 days.YES☒NO☐ Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submittedpursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that theregistrant was required to submit such files).YES☒NO☐ Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smallerreporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “non-accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act. Large Accelerated FilerNon-accelerated Filer ☐☒☒ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period forcomplying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.☒ Indicate by check mark whether the registrant has filed a report on and attestation to its management’s assessment of the effectivenessof its internal control over financ